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Abstract: Central nervous system (CNS) metastasis carries a significant morbidity and mor-
tality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).
Next-generation ALK tyrosine kinase inhibitors (TKIs) are highly CNS-penetrant and have
demonstrated remarkable intracranial activity across clinical studies, and yet radiation remains
the mainstay of treatment modality against CNS metastasis. We have previously reported
alectinib can induce CNS radiation necrosis even after a remote history of radiation (7 years
post-radiation). Lorlatinib is another potent next-generation ALK TKI that can overcome many
ALK resistance mutations and has been shown to have excellent activity in patients with baseline
CNS metastasis. Here we report two ALK-rearranged NSCLC patients who developed radiation
necrosis shortly after initiating lorlatinib following progression on the sequential treatment of
crizotinib, alectinib, and brigatinib. In both cases, radiation necrosis is evidenced by serial MRI
images and histological examination of the resected CNS metastasis that had previously been
radiated. Our cases highlight the importance of recognizing CNS radiation necrosis that may
mimic disease progression in ALK-rearranged NSCLC treated with and potentially precipated by
next-generation ALK TKIs.
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Introduction
Central nervous system (CNS) metastasis carries a significant morbidity and mor-
tality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
(NSCLC). Among the three most common receptor tyrosine kinase (RTK) fusions
in NSCLC (ALK, ROS1, RET), ALK-rearranged NSCLC has the highest cumulative
incidence of CNS metastasis over the course of the disease process with a projected
cumulative incidence of 65% at 6 years from diagnosis.1 Lorlatinib is a highly
CNS-penetrant and potent third-generation ALK tyrosine kinase inhibitor (TKI)
that can overcome almost all of the crizotinib-resistant ALK mutations including
C1156Y, I1171N/S/T, F1174C, L1196M, D1203N, G1269A, as well as the solvent
front mutation G1202R.2,3 Given its excellent CNS penetration, the efficacy of
lorlatinib has been observed even in patients with CNS metastasis after disease
progression on other second-generation ALK TKIs.4,5 Lorlatinib has been approved
by the US FDA in November 2018 for the treatment of advanced ALK-rearranged
NSCLC after progression on first-line alectinib or ceritinib or after crizotinib and at
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least one other ALK TKI.6 While oligometastatic CNS
metastasis could be considered for surgical resection
when anatomically feasible, lung cancer patients are often-
times found with multiple CNS metastases that are typi-
cally treated with radiation (whole brain or stereotactic
radiation). Thus, lorlatinib is frequently used in ALK-
rearranged NSCLC patients with previously radiated
CNS metastasis. Here we report two cases of radiation
necrosis requiring neurosurgical resection during lorlatinib
treatment following disease progression on second-
generation ALK TKIs.
Case Presentation
Case 1 patient is a 45-year-old Caucasian woman with
a former light-smoking history who presented with stage IV
lung adenocarcinoma including CNS metastasis, bilateral
lung involvement, and left iliac bony metastasis.
Stereotactic radiosurgery (SRS) was given to the right frontal
lobe, right occipital lobe, and right cerebellar lesions (2000
cGy in a single fraction to each lesion; Figure 1A).Molecular
profiling of the lung mass was positive for ALK by FISH
(62% split signal) and negative for activating EGFR muta-
tions and ROS1 fusion. Crizotinib at 250 mg twice daily was
started but it was switched to alectinib 9 months later due to
CNS progression. However, after being on alectinib for 6
months, CNS progression continued with worsening known
brain lesions (Figure 1A) and a new left frontal lobe lesion
for which whole-brain radiation (WBRT) was given (3750
cGy in fifteen fractions). Alectinib was held during WBRT
and then switched to brigatinib which achieved stable CNS
control for 4 months until a new left cerebellar lesion
appeared. This lesion subsequently resolved 2 months after
switching to lorlatinib, but 3 additional months later the
patient presented with headaches, nausea, and vomiting and
was found to have worsening edema around the right frontal
lobe lesion (Figure 1A). She underwent neurosurgical resec-
tion of this lesion and pathology was consistent with radia-
tion necrosis (Figure 1B). Lorlatinib was held for 1 week
peri-operatively. Six months after resuming lorlatinib, the
patient again developed headaches due to worsening edema
around the right occipital lobe lesion (Figure 1A). Pathology
from the second resection was again consistent with radiation
necrosis (Figure 1B). The patient has remained on lorlatinib
since. Throughout the treatment course, her extracranial dis-
ease was responding to various ALK TKIs with a confirmed
partial response (PR).
Case 2 patient is a 75-year-old never-smoking African
American woman who was diagnosed with stage IV lung
adenocarcinoma in October 2006. She had received multiple
lines of chemotherapy until July 2014 when a biopsy of
a liver lesion revealed an EML4-ALK variant 1 fusion. She
achieved a PR on crizotinib for 16 months. Due to CNS
progression, crizotinib was switched to alectinib and she
achieved a PR for another 27 months until further progres-
sion of a left frontal lobe lesion (Figure 2A). SRS was given
to this lesion (1800 cGy in single fraction) and three other
small lesions while continuing alectinib. Three months later,
she received additional SRS (2000 cGy in single fraction
each) to six new asymptomatic small CNS lesions.
Subsequently, alectinib was switched to brigatinib but the
first surveillance scan after 7 weeks of treatment with briga-
tinib revealed an increase in the size of the left frontal lobe
lesion with increased surrounding edema (Figure 2A), along
with three additional punctate enhancing lesions. Within 2
weeks of switching from brigatinib to lorlatinib, the patient
developed altered mental status due to further increased
edema around the left frontal lobe lesion (Figure 2A).
Pathology from resection of this lesion revealed radiation
necrosis (Figure 2B). Currently, she is on a reduced dose of
lorlatinib at 50 mg once daily. The schematic summary of the
treatment course of each case is shown in Figures 1C and 2C
respectively. Both patients have provided a written informed
consent to have the case details published and institutional
approval was not required.
Discussion
Case 1 illustrates a relatively common clinical scenario with
RTK fusion-driven lung cancer where there may be contin-
uous intracranial progression despite extracranial disease
response with various ALK TKIs. Repeated radiation is
often delivered to treat new and/or progressing CNS metas-
tasis. In the randomized ALEX trial comparing the first-line
crizotinib with alectinib, the cumulative incidence of CNS
metastasis at 12 months was 8.6% for alectinib and 50.4%
for crizotinib among patients who had received prior radia-
tion for CNS metastasis.7 Lorlatinib has demonstrated sig-
nificant intracranial activity even after disease progression
on alectinib or ceritinib with an intracranial response rate of
63.0% and a median duration of intracranial response of
14.5 months in ALK-rearranged NSCLC with exposure to at
least one prior ALK TKI.5 We have previously reported that
radiation necrosis necessitating neurosurgical resection
could occur with alectinib.8,9 In one case, radiation necrosis
occurred after 7 years from the last radiation treatment and
12 months into alectinib treatment.9 While radiation necro-
sis did not occur during alectinib treatment in our case 1
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patient, symptomatic radiation necrosis occurred twice both
requiring neurosurgical resection during lorlatinib treat-
ment with the second episode of radiation necrosis occur-
ring after 11 months into lorlatinib treatment. Radiation
necrosis is a known side effect of radiation treatment.10,11
While in case 1 both radiation necrosis could have been
attributed to radiation itself, we hypothesize that lorlatinib
may have conceivably accelerated the development of
radiation necrosis. Due to its potent ALK inhibitory activity,
any residual tumor growth in previously radiated CNS
metastasis could have been inhibited by lorlatinib poten-
tially even triggering further tumor necrosis. In case 1, we
could not rule out the possibility of radiation necrosis start-
ing at the time of switching from alectinib to brigatinib, but
the appearance of three new punctate lesions necessitated
the transition from brigatinib to lorlatinib due to limited
clinical efficacy data on sequencing from alectinib to
brigatinib.12 Radiation necrosis rapidly developed 2 weeks
after initiating lorlatinib. As such, there remains a possibility
of lorlatinib accelerating the occurrence of radiation necro-
sis potentially initiated during brigatinib treatment.
Concurrent use of EGFR TKIs with upfront WBRT to
SRS has been identified as a significant risk factor for devel-
oping radiation necrosis.13 Interestingly, ALK-rearranged
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Figure 1 (A) Serial MRI of the brain demonstrating intracranial lesions treated with stereotactic radiosurgery (SRS) (blue circles) and craniotomy (yellow and green circles).
Progressive cerebral edema in the right frontal and occipital lobes during lorlatinib treatment is shown. Jan 2016: prior to SRS; Nov 2016: progression on crizotinib; Jun 2017:
progression on alectinib prior to whole-brain radiation; Sep 2017: progression on brigatinib; May 2018: radiation necrosis #1; Oct 2018: radiation necrosis #2; Dec 2018: lorlatinib
resumed post-operatively. (B) Histological slides (40X magnification) from the first craniotomy revealed extensive necrosis of gray matter (B1) and severe hyalinization of white
matter with surrounding necrosis (B2). Histological slides (100Xmagnification) from the second craniotomy also demonstrated gray matter sparing and white matter necrosis (B3).
Note the vessels in the background of extensive white matter necrosis (B4). Red arrows point towards areas of necrosis. (C) Schematic summary of the treatment course.
Abbreviations: LN, lymph node; SRS, stereotactic radiosurgery; WBRT, whole-brain radiation.
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Figure 2 (A) MRI of the brain demonstrating the left frontal lobe lesion indicated by the red circles over the course of sequential treatmentwith alectinib, brigatinib, and lorlatinib. Jan 2018: the
enhancing left superior frontal lesion while on alectinib; Apr 2018: progression of the left superior frontal lesion leading to stereotactic radiosurgery (SRS) while on alectinib; Jul 2018: alectinib
switched to brigatinib due to asymptomatic CNS progression (not shown on this slice of scan) leading to SRS;Oct 2018: brigatinib switched to lorlatinib followed by radiation necrosis; Jan 2019:
lorlatinib resumed post-operatively. (B) Histological slides (40X, 100X, 200Xmagnification) from the resected CNS lesion showed extensive necrosis of gray matter. Red arrows point towards
areas of necrosis. (C) Schematic summary of the treatment course.
Abbreviation: SRS, stereotactic radiosurgery.
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NSCLC has also been identified as a risk factor for develop-
ing radiation necrosis (hazard ratio of 6.36).14 Large-scale
multi-institutional analyses will be required to determine
whether the increased risk of radiation necrosis in ALK-
rearranged NSCLC is the result of inherent tumor biology,
a high incidence of CNS metastasis, repeated CNS radiation,
systemic treatment with highly CNS-penetrant ALKTKIs, or
a combination of these factors. When feasible, upfront use of
CNS-penetrant ALK TKIs prior to radiation even in patients
with untreated large or symptomatic CNS metastasis should
be explored.15
Conclusion
With the advent of multiple ALK TKIs, the median overall
survival of ALK-rearranged NSCLC patients treated with
sequential ALK TKIs can be up to 7.5 years;16 and the
median overall survival from stage IV disease can be at
least 6.8 years.17 ALK-rearranged NSCLC patients are likely
to develop CNSmetastasis during their disease course requir-
ing radiation treatment. Acknowledging the fact that radia-
tion necrosis could occur during a later line of lorlatinib
treatment is critical as it often mimics disease progression
which may lead to premature discontinuation of lorlatinib.
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